ATG16L1 and hepatocellular carcinoma: To confirm that ATG5 or ATG16L1 downregulation was responsible for the effects of miR-142-3p on HCC cell sensitivity to sorafenib, we performed “rescue assays” in which ATG5 or ATG16L1 was overexpressed in a plasmid lacking the miR-142-3p response element.